In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE). The US regulator has cleared ...

Meanwhile, in July the FDA missed its review deadline for Takeda's Eohilia (budesonide oral suspension) treatment for the inflammatory disease eosinophilic oesophagitis, while the EMA extended the ...

The latest edition of EMJ Oncology is out now, featuring coverage from the 2024 European Society for Medical Oncology Congress… ...

The first PPI to reach the market was omeprazole, which is indicated for the treatment of duodenal and gastric ulcers, gastro-oesophageal reflux disease, erosive oesophagitis, hypersecretory ...

Conclusions: Fast track endoscopy in subjects fulfilling current criteria for suspected upper gastrointestinal malignancy results in a significant yield of cancer (∼4%) and serious benign diseases ...